| Erythropoietin is equally effective as fresh-blood transfusion at reducing infarct size in anemic rats. | |
| | |
MedLine Citation:
|
PMID: 20693887 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We recently demonstrated that transfusion of anemic animals up to 100 g/L hemoglobin with fresh blood protects the heart from ischemic injuries following myocardial infarction. Erythropoietin has cardioprotective effects independent of its erythropoietic activity. The objective of this study was to compare the cardioprotective effects of erythropoietin treatment to fresh-blood transfusion in anemic rats after acute myocardial infarction. DESIGN: Randomized animal study. SETTING: University laboratory. SUBJECTS: Male Sprague-Dawley rats weighing 200-300 g. INTERVENTION: Myocardial infarction was induced by coronary artery ligation in 76 rats, 55 of which were anemic (80-90 g/L) and 21 of which had normal hemoglobin levels. Animals were randomized to erythropoietin (2000 units/kg), fresh-blood transfusion to 100 g/L hemoglobin, or saline-treatment groups immediately following myocardial infarction. MEASUREMENTS AND MAIN RESULTS: At 24 hrs after myocardial infarction, cardiac function and infarct size were determined. Myocardial apoptosis was determined by caspase-3 activity and terminal deoxynucleotidyl transferase d-UTP nick end labeling (TUNEL) assay. Infarct size was significantly decreased in anemic rats treated with erythropoietin or blood transfusion compared to those in the saline-treatment group. Cardiac function, as measured by maximal positive and minimal negative first derivatives of left ventricular pressure, was better preserved in the normal hemoglobin groups and the erythropoietin- or transfusion-treated anemic animals compared to saline-treated anemic animals. Myocardial caspase-3 activity and TUNEL-positive nuclei were significantly increased in anemic rats but were decreased by erythropoietin treatment or red blood cell transfusion. CONCLUSIONS: Erythropoietin treatment is equally effective as fresh-blood transfusion in anemic rats after acute myocardial infarction at reducing infarct size, myocardial apoptosis, and improving cardiac function. |
| | |
Authors:
|
Anargyros Xenocostas; Houxiang Hu; Nicolas Chin-Yee; Xiangru Lu; Ian Chin-Yee; Qingping Feng |
Related Documents
:
|
7291297 - Diltiazem pretreatment reduces experimental myocardial infarct size in rat. 19288277 - Antioxidant defense of betaine against isoprenaline-induced myocardial infarction in rats. 1008997 - Comparative effects of cortisone, dianabol and enovid on isoprenaline-induced myocardia... 8124817 - Exposure to environmental tobacco smoke increases myocardial infarct size in rats. 2009807 - Laboratory parameters to monitor safety and efficacy during thrombolytic therapy. 12132287 - Relationship between clinical and echocardiography-derived parameters and atrial activa... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Critical care medicine Volume: 38 ISSN: 1530-0293 ISO Abbreviation: Crit. Care Med. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-20 Completed Date: 2010-11-02 Revised Date: 2011-01-07 |
Medline Journal Info:
|
Nlm Unique ID: 0355501 Medline TA: Crit Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 2215-21 Citation Subset: AIM; IM |
Affiliation:
|
Centre for Critical Illness, Research Lawson Health Research Institute, Canadian Blood Services, Ontario, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia
/
complications*,
drug therapy,
therapy Animals Apoptosis Blood Pressure / physiology Blood Transfusion* Cardiotonic Agents / therapeutic use* Caspase 3 / metabolism Erythropoietin / therapeutic use* Heart / physiopathology Heart Rate / physiology Hemoglobins / analysis In Situ Nick-End Labeling Male Myocardial Infarction / complications, drug therapy*, physiopathology, therapy Myocardium / enzymology Rats Rats, Sprague-Dawley |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Hemoglobins; 11096-26-7/Erythropoietin; EC 3.4.22.-/Caspase 3 |
| Comments/Corrections | |
Erratum In:
|
Crit Care Med. 2011 Jan;39(1):243 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia.
Next Document: The effects of epinephrine on outcomes of normothermic and therapeutic hypothermic cardiopulmonary r...